Dr. Loeb on the Results of Active Surveillance for Prostate Cancer

Stacy Loeb, MD
Published: Monday, Aug 28, 2017



Stacy Loeb, MD, assistant professor of urology and population health at NYU Langone School of Medicine, discusses the results and impact of active surveillance on patients with prostate cancer.

Of the patients who could be considered candidates for active surveillance, one-fifth of those patients had higher Decipher scores, indicating a greater risk of aggressive disease, states Loeb. However, there were patients with intermediate-risk disease who had low Decipher scores.

Now that there are more testing options, patients do not have to rely on one biopsy test, explains Loeb. There are imaging and genomic tests that can give a patient more data and help determine if they are candidates for active surveillance.
 


Stacy Loeb, MD, assistant professor of urology and population health at NYU Langone School of Medicine, discusses the results and impact of active surveillance on patients with prostate cancer.

Of the patients who could be considered candidates for active surveillance, one-fifth of those patients had higher Decipher scores, indicating a greater risk of aggressive disease, states Loeb. However, there were patients with intermediate-risk disease who had low Decipher scores.

Now that there are more testing options, patients do not have to rely on one biopsy test, explains Loeb. There are imaging and genomic tests that can give a patient more data and help determine if they are candidates for active surveillance.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x